Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7810060 | 0.79 | THRB (0.32) | — | |
| SCHEMBL2510884 | 0.78 | TSHR (0.39) | — | |
| SCHEMBL8734845 | 0.76 | — | — | |
| SCHEMBL1663096 | 0.76 | — | — | |
| SCHEMBL7705963 | 0.76 | — | — | |
| SCHEMBL6586426 | 0.76 | CETP (0.31) | — | |
| SCHEMBL15285469 | 0.75 | — | — | |
| SCHEMBL20985453 | 0.74 | LMNA (0.35) | TDP1 | |
| SCHEMBL9174410 | 0.72 | — | — | |
| SCHEMBL4447065 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2640730-B1 | PROCESSES FOR PREPARATION OF EVEROLIMUS AND INTERMEDIATES THEREOF | BIOCON LTD (IN) | 2019-08-07 | — | — | EP | claimed |
| US-9079921-B2 | Processes for preparation of Everolimus and intermediates thereof | BIOCON LIMITED (IN) | 2015-07-14 | — | — | US | claimed |
| EP-2640730-A1 | PROCESSES FOR PREPARATION OF EVEROLIMUS AND INTERMEDIATES THEREOF | Biocon Limited (IN) | 2013-09-25 | — | — | EP | claimed |
| US-20130225823-A1 | PROCESSES FOR PREPARATION OF EVEROLIMUS AND INTERMEDIATES THEREOF | BIOCON LIMITED (IN) | 2013-08-29 | — | — | US | claimed |
| WO-2012066502-A1 | PROCESSES FOR PREPARATION OF EVEROLIMUS AND INTERMEDIATES THEREOF | BIOCON LIMITED (IN) | 2012-05-24 | — | — | WO | claimed |
| EP-4302827-A2 | RAPAMYCIN ANALOGS AND USES THEREOF | JANSSEN Pharmaceutica NV (BE) | 2024-01-10 | — | — | EP | disclosed |
| US-20220211630-A1 | SOLID NANOPARTICLE FORMULATION OF WATER INSOLUBLE PHARMACEUTICAL SUBSTANCES WITH REDUCED OSTWALD RIPENING AND IMMEDIATE DRUG RELEASE FOLLOWING INTRAVENOUS ADMINISTRATION | AUSTIN BIOSCIENCES CORP. | 2022-07-07 | — | — | US | disclosed |
| US-20210220339-A1 | RAPAMYCIN ANALOGS AND USES THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2021-07-22 | — | — | US | disclosed |
| EP-2640730-B1 | PROCESSES FOR PREPARATION OF EVEROLIMUS AND INTERMEDIATES THEREOF | BIOCON LTD (IN) | 2019-08-07 | — | — | EP | disclosed |
| US-9938297-B2 | Process for the synthesis of everolimus and intermediates thereof | Cipia Limited (IN) | 2018-04-10 | — | — | US | disclosed |
| US-9828406-B2 | Antitumor agent | KINKI UNIVERSITY (JP) | 2017-11-28 | — | — | US | disclosed |
| EP-2716293-B1 | ANTI-TUMOR AGENT | UNIV KINKI (JP) | 2017-09-06 | — | — | EP | disclosed |
| EP-2027130-A1 | 36 -DES (3 -METHOXY-4 -HYDROXYCYCLOHEXYL) 36 - (3 -HYDROXYCYCLOHEPTYL) DERIVATIVES OF RAPAMYCIN FOR THE TREATMENT OF CANCER AND OTHER DISORDERS | Biotica Technology Limited (GB) | 2009-02-25 | — | — | EP | disclosed |
| US-20080188511-A1 | 39-Desmethoxy Derivatives of Rapamycin | BIOTICA TECHNOLOGY LIMITED (GB) | 2008-08-07 | — | — | US | disclosed |
| EP-1863803-A2 | SUBSTITUTED PIPERIDINES | Speedel Experimenta AG (CH) | 2007-12-12 | — | — | EP | disclosed |
| WO-2007135411-A1 | 39-DESMETHOXY-39-METHYL DERIVATIVES OF RAPAMYCIN. | BIOTICA TECHNOLOGY LTD. (GB) | 2007-11-29 | — | — | WO | disclosed |
| WO-2007135397-A1 | 36 -DES (3 -METHOXY-4 -HYDROXYCYCLOHEXYL) 36 - (3 -HYDROXYCYCLOHEPTYL) DERIVATIVES OF RAPAMYCIN FOR THE TREATMENT OF CANCER AND OTHER DISORDERS | BIOTICA TECHNOLOGY LIMITED (GB) | 2007-11-29 | — | — | WO | disclosed |
| EP-1856129-A1 | 39-DESMETHOXY DERIVATIVES OF RAPAMYCIN | Biotica Technology Limited (GB) | 2007-11-21 | — | — | EP | disclosed |
| WO-2006103277-A2 | 2 , 4 , 5-SUBSTITUTED PIPERIDINES AS RENIN INHIBITORS | SPEEDEL EXPERIMENTA AG (CH) | 2006-10-05 | — | — | WO | disclosed |
| WO-2006095185-A1 | 39-DESMETHOXY DERIVATIVES OF RAPAMYCIN | BIOTICA TECHNOLOGY LIMITED (GB) | 2006-09-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210220339-A1 | RAPAMYCIN ANALOGS AND USES THEREOF | RICTOR, MTOR, RPTOR | TDP1 3074/4885 |
| US-20080188511-A1 | 39-Desmethoxy Derivatives of Rapamycin | RICTOR, MTOR, MALT1 | TDP1 2801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.